Delivery Order SPE2DB25D9305-SPE2DB25FQAET
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, which became effective on July 23, 2025, with an ultimate completion date of July 24, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. for 120 capsules of Xtandi 40 mg on September 15, 2025, with completion targeted for September 16, 2025. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, was selected under a firm fixed-price delivery order contract with no set-aside designation. The order will be fulfilled from the contractor's Park Ridge, Illinois...
- The Defense Logistics Agency awarded a delivery order valued at $4,311.35 to DMS Pharmaceutical Group Inc. on September 3, 2025, for the supply of Xtandi 40 mg capsules (120-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order for delivery to Park Ridge, IL. The contract utilizes a firm fixed-price structure with an ultimate completion date of September 4, 2025, and no set-aside designation...
- The Defense Logistics Agency awarded a $4,169.59 firm fixed-price delivery order to DMS Pharmaceutical Group Inc. on June 18, 2025, for the supply of Xtandi 80 mg tablets (60-count units). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform the work at its primary location. This delivery order was issued without a set-aside designation, and the ultimate completion date is June 20, 2025. The contract leverages DMS...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 22, 2025, with an ultimate completion date of July 23, 2025, is structured as a firm fixed-price delivery order with no set-aside designation. The awardee, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will fulfill this order from its location in the same city....
- The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. on September 9, 2025, for the supply of Xtandi 40 mg tablets (120-count units). DMS Pharmaceutical Group, a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this order at its Park Ridge location with an ultimate completion date of September 10, 2025. This delivery order was issued without a set-aside designation,...
- The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 80 mg tablets (60-count units). This award, issued on June 3, 2025, with an ultimate completion date of June 4, 2025, represents a single delivery order under DMS Pharmaceutical Group's existing Indefinite Delivery Contract with DLA valued at approximately $500 million through November 2026. The delivery will be fulfilled from the contractor's...
- The Defense Logistics Agency awarded a delivery order valued at $8,339.18 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xtandi 80 mg tablets (60-count units). The contract, issued on July 11, 2025, with an ultimate completion date of July 14, 2025, operates under a firm fixed-price structure with no set-aside designation. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite...
- The Defense Logistics Agency awarded a $4,169.59 delivery order to DMS Pharmaceutical Group Inc. on September 5, 2025, for the supply of Xtandi 80 mg tablets (60-count units). This firm fixed-price delivery order, designated 4569340914, is scheduled for completion by September 8, 2025, and will be performed at the vendor's facility in Park Ridge, Illinois. The contract carries no set-aside designation, allowing DMS Pharmaceutical Group to compete on an open basis despite its status as a...
- The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for 60 tablets of Xtandi 80 mg on September 2, 2025, with an ultimate completion date of September 3, 2025. This firm fixed-price delivery order was issued without a set-aside designation and represents a pharmaceutical supply to support Department of Defense healthcare requirements. DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge,...
- SPE2DB25D9305Indefinite Delivery Contract
- SPE2DB25D9305-SPE2DB25FQAETDelivery Order
The Defense Logistics Agency awarded a delivery order valued at $4,169.59 to DMS Pharmaceutical Group Inc. for the supply of Xtandi 40 mg tablets (120-count packages). DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, will perform this contract at its facility in Park Ridge, IL. The delivery order was awarded on May 13, 2025, with an ultimate completion date of May 14, 2025, under firm fixed-price terms with no set-aside designation applied. This delivery order is issued under DMS Pharmaceutical Group's larger Indefinite Delivery Contract with the Defense Logistics Agency valued at $499,999,999 and effective through November 2026. The parent contract, executed under the SPE2DB program, enables DLA to issue firm fixed-price delivery orders for a comprehensive range of pharmaceutical products supporting medical supply needs of military health facilities worldwide. Xtandi, a prescription oncology medication, falls within the extensive portfolio of branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables that DMS Pharmaceutical Group is authorized to supply through this vehicle. The company's positioning as a critical supplier in the federal pharmaceutical supply chain provides direct distribution of prescription drugs and pharmacy services to Department of Defense healthcare sites.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $4.2k | 5/13/25 |